Omicron, a small molecule that is sometimes used to stop tumors from spreading, can be given to many people, Pfizer said in a statement. (PHOTO: FILE, AUSTRALIA PRESS/HANDOUT)
Pfizer said it was in development of a drug that is effective against an ovarian cancer protein and it looked promising, the company reported Friday.
Omicron, a small molecule that is sometimes used to stop tumors from spreading, can be given to many people, Pfizer said in a statement. It is in clinical testing for ovarian cancer patients, as well as in lung, breast and other types of cancer. The company is in phase 2 testing — the start of trials where safety, tolerability and effectiveness are tested — on the drug as a treatment for ovarian cancer.
Pfizer’s breast cancer drug palbociclib has already been approved, but its first indication of efficacy against tumors with esophageal and breast cancer is only phase 2.
The drug that was targeted to omicron, acertarib, has been approved in Europe. Pfizer said it will study acertarib in prostate cancer and other diseases. But the company said acertarib showed promise for ovarian cancer patients. The drug targets a protein called an inhibitor of apoptosis protein.